Centrally acting antiadrenergic (versus unexposed) - Medication and Pregnancy KB

Centrally acting antiadrenergic (versus unexposed) updated on 03-11-2025

Very preterm (28 to 32 weeks)

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S17152 R71935	Al Khalaf - Methyldopa (Controls unexposed, disease free), 2022	Very preterm birth (less than 32 weeks)	during pregnancy (anytime or not specified)	retrospective cohort (claims database)	unexposed, disease free excluded	Adjustment: No Indications Antihypertensive: Only chronic hypertension indication	5.93 [4.84;7.26] ^C excluded (control group)	100/1,760 17,507/1,739,944	17,607	1,760		ref
S17149 R71914	Al Khalaf - Methyldopa (Controls unexposed, sick), 2022	Very preterm birth (less than 32 weeks)	during pregnancy (anytime or not specified)	retrospective cohort (claims database)	unexposed, sick	Adjustment: No Indications Antihypertensive: Only chronic hypertension indication	2.26 [1.77;2.88] ^C	100/1,760 203/7,809	303	1,760		ref
					Total	1 studies	2.26 [1.77;2.88]		303	1,760
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 17152